Back to top
more

Semler Scientific (SMLR)

(Real Time Quote from BATS)

$27.50 USD

27.50
808,457

-1.61 (-5.53%)

Updated Sep 17, 2025 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aniruddha Ganguly headshot

MicroStrategy Rises 28% Year to Date: Buy, Sell or Hold the Stock?

by Aniruddha Ganguly

MSTR is up 27.9% year to date, fueled by bitcoin gains and rising subscriptions, but a premium valuation makes the stock risky.

Zacks Equity Research

Zacks Investment Ideas feature highlights: SPY, QQQ, MicroStrategy, GameStop and Semler Scientific

by Zacks Equity Research

SPY, QQQ, MicroStrategy, GameStop and Semler Scientific are part of the Zacks Investment Ideas article.

Andrew Rocco headshot

The Great Decoupling: Bitcoin Carves its Own Path

by Andrew Rocco

Bitcoin's unique value proposition as a scarce, decentralized, and globally accessible asset increasingly resonates with international investors. Stock Strategist Andrew Rocco breaks down the details.

Andrew Rocco headshot

Bitcoin Q2 2025: Bullish Signals Emerge After Pullback

by Andrew Rocco

Despite a pullback from its 2024 high, Bitcoin's outlook for Q2 remains bright. Stock Strategist Andrew Rocco breaks it down.

Andrew Rocco headshot

Is Bitcoin Set for a Big Rally? $100K Breakout, Coinbase Win Say Yes

by Andrew Rocco

Several bullish factors signal a major Bitcoin rally, including the "Livermore Round # Rule??? and the dismissal of the Coinbase SEC case. Stock Strategist Andrew Rocco explains.

Andrew Rocco headshot

Bull of the Day: Coinbase (COIN)

by Andrew Rocco

Coinbase, the leading US crypto exchange, is poised to benefit dramatically from a pro-crypto Trump administration, potential new altcoin ETFs, and increased corporate adoption of Bitcoin.

Andrew Rocco headshot

Coinbase (COIN): A Crypto Powerhouse

by Andrew Rocco

Coinbase is the true market leader in the crypto exchange industry. The stock should benefit from global crypto adoption, strategic partnerships, and a strong balance sheet.

Andrew Rocco headshot

3 Crypto Stocks to Buy Now: IBIT, COIN, MARA

by Andrew Rocco

Political changes, public company adoption, and the $100k price "magnet" are three reasons Bitcoin and Bitcoin proxies are poised to move higher into year-end. Stock Strategist Andrew Rocco divulges 3 crypto stocks to buy now.

Andrew Rocco headshot

Bitcoin: Time to Buy the Dip?

by Andrew Rocco

Bitcoin's weakness is likely to be short-lived due to temporary headwinds like the Mt. Gox supply shock. Stock Strategist Andrew Rocco explains the opportunity.

Zacks Equity Research

After Plunging 30.3% in 4 Weeks, Here's Why the Trend Might Reverse for Semler Scientific Inc. (SMLR)

by Zacks Equity Research

Semler Scientific Inc. (SMLR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates

by Zacks Equity Research

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 24.32% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

by Zacks Equity Research

The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.

Zacks Equity Research

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

by Zacks Equity Research

Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.

Zacks Equity Research

Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

Zacks Equity Research

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Zacks Equity Research

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Zacks Equity Research

McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout

by Zacks Equity Research

McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.

Zacks Equity Research

Zacks Industry Outlook Highlights ShockWave Medical, Semler Scientific and Asensus Surgical

by Zacks Equity Research

ShockWave Medical, Semler Scientific and Asensus Surgical are part of Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is disrupting the trend.

Zacks Equity Research

Semler Scientific Inc. (SMLR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 27.50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Strength Seen in EDAP TMS S.A. (EDAP): Can Its 13.4% Jump Turn into More Strength?

by Zacks Equity Research

EDAP TMS S.A. (EDAP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Semler Scientific Inc. (SMLR) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of -19.61% and 5.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?